☆ 4.6 Article

A Novel Prognostic Nomogram for Predicting Survival of Hormone Receptor-Positive and HER2 Negative Advanced Breast Cancer Among the Han-Population

FRONTIERS IN ONCOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Medicine, Research & Experimental

Construction and validation of prognostic nomogram for metaplastic breast cancer

Yongfeng Li et al.

Summary: This study aimed to develop nomogram models for predicting overall survival and cancer-specific survival of patients with metaplastic breast carcinoma (MBC). The study collected data from 1973 to 2015 and used Cox analyses and calibration plots to evaluate model performance. The results showed that the nomogram models had good accuracy in predicting patient survival.

BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES (2022)

Add to Collection

Article Oncology

ER-/PR plus breast cancer: A distinct entity, which is morphologically and molecularly close to triple-negative breast cancer

Francoise Beltjens et al.

Summary: The study confirmed that ER-/PR+ breast cancers are an extremely rare but real subtype, morphologically and histologically similar to triple-negative tumors, with more aggressive phenotypes and differing responses to therapies and clinical outcomes. The likely involvement of SUZ12 in their biology offers potential for the development of new therapeutic alternatives.

INTERNATIONAL JOURNAL OF CANCER (2021)

Add to Collection

Article Medicine, General & Internal

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

A. Bardia et al.

Summary: Patients with metastatic triple-negative breast cancer treated with Sacituzumab govitecan had significantly longer progression-free and overall survival compared to standard chemotherapy, but experienced more frequent myelosuppression and diarrhea as adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival

Y. Fan et al.

Summary: This study revealed significant clinical differences between single HR-positive and double HR-positive/double HR-negative subtypes in patients with HER2-positive breast cancer. The nomogram-based model accurately predicted survival outcomes, suggesting the need for tailored treatment strategies based on subtype for optimal outcomes.

ESMO OPEN (2021)

Add to Collection

Article Medicine, General & Internal

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

R. K. Murthy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Breast Cancer, Version 3.2020

William J. Gradishar et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)

Add to Collection

Article Oncology

Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China

Shaoyan Lin et al.

BREAST (2020)

Add to Collection

Article Oncology

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

F. Cardoso et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Review Medicine, General & Internal

Breast Cancer Treatment A Review

Adrienne G. Waks et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

Add to Collection

Article Oncology

Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?

Rui-Mei Feng et al.

CANCER COMMUNICATIONS (2019)

Add to Collection

Article Oncology

Comparison of prognostic nomograms based on different nodal staging systems in patients with resected gastric cancer

Zi-Xian Wang et al.

JOURNAL OF CANCER (2017)

Add to Collection

Article Oncology

Cancer Statistics in China, 2015

Wanqing Chen et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2016)

Add to Collection

Article Oncology

Impact of breast cancer subtypes and patterns of metastasis on outcome

Karin Kast et al.

BREAST CANCER RESEARCH AND TREATMENT (2015)

Add to Collection

Article Oncology

Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?

D. J. A. Lobbezoo et al.

BRITISH JOURNAL OF CANCER (2015)

Add to Collection

Review Pharmacology & Pharmacy

Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature

Cagatay Arslan et al.

EXPERT OPINION ON THERAPEUTIC TARGETS (2011)

Add to Collection

Article Oncology

Survival differences among women with de novo stage IV and relapsed breast cancer

S. Dawood et al.

ANNALS OF ONCOLOGY (2010)

Add to Collection

Article Oncology

Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register

Javier Puente et al.

BREAST CANCER RESEARCH AND TREATMENT (2010)

Add to Collection

Article Oncology

Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

C. Simmons et al.

ANNALS OF ONCOLOGY (2009)

Add to Collection

Article Oncology

Prognostic factors in 1038 women with metastatic breast cancer

R. Largillier et al.

ANNALS OF ONCOLOGY (2008)

Add to Collection

Article Medicine, General & Internal

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

Lisa A. Carey et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)

Add to Collection

Article Multidisciplinary Sciences

Gene expression profiling predicts clinical outcome of breast cancer

LJ van't Veer et al.

NATURE (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.